International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer

Summary

The goal of this international, multicenter, prospective observational study is to improve prognostication and prediction of failure pattern for nasopharyngeal carcinoma (NPC), in order to provide more accurate guidance for personalized treatment decision. Firstly, we aim to improve the fundamental TNM staging system \[The American Joint Committee on Cancer(AJCC)/Union for International Cancer Control(UICC) TNM Version-Nine\] based on universally assessable anatomical parameters. Secondly, we aim to further refine prognostication for individual patients by integrating anatomical TNM parameters with non-anatomical factors and molecular biomarkers. In addition to the core group of participating centers from China (including Hong Kong) where NPC is most prevalent, the study will enrol patients from multiple countries/regions including those from non-endemic areas to provide global data. Patients treated with contemplary treatment methods during October 2025 to September 2026 will be recruited and they will be followed up for 5 years to generate detailed records for robust evaluation.

Key Questions:

* To achieve optimal improvement of anatomically based AJCC/UICC TNM Classification for global application
* To achieve precise prediction of failure pattern for individual patients by integration of TNM system and non-anatomical prognostic factors/molecular biomarkers Recruited patients with confirmed histological diagnosis of NPC will undergo standard clinical evaluations and receive treatment per institutional guidelines.

The anatomical extent of disease at presentation will be evaluated by experienced radiologists and oncologists. The patient will be followed up for 5 years and clinical outcome will be recorded for analyses on correlation with prognostic factors.

This study will be another important milestone for NPC staging because firstly, this is the first time that the data are based on prospective data to ensure comprehensive coverage of all essential evidence; and secondly, this is the first time that centers from non-endemic countries/regions will also participate to ensure that the final recommendations are globally applicable. The findings will provide valuable evidence for the development of the AJCC/UICC TNM Version-Ten staging system and prognostic system to improve risk stratification for designing personalized treatment strategy, ultimately leading to improvement of patient outcome and patient selection for future research worldwide.

Conditions

• Nasopharyngeal Cancinoma (NPC)

Sponsors & Collaborators

• Fujian Cancer Hospital

  collaborator OTHER_GOV

• Chinese Academy of Medical Sciences

  collaborator OTHER

• Jiangxi Provincial Cancer Hospital

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• Chongqing University Cancer Hospital

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Sichuan Cancer Hospital and Research Institute

  collaborator OTHER

• First Affiliated Hospital of Fujian Medical University

  collaborator OTHER

• Queen Mary Hospital, Hong Kong

  collaborator OTHER

• The Queen Elizabeth Hospital

  collaborator OTHER

• Pamela Youde Nethersole Eastern Hospital

  collaborator OTHER

• Princess Margaret Hospital, Hong Kong

  collaborator OTHER_GOV

• United Christian Hospital

  collaborator OTHER

• Prince of Wales Hospital, Shatin, Hong Kong

  collaborator OTHER

• Fudan University

  collaborator OTHER

• Hunan Cancer Hospital

  collaborator OTHER

• National Cancer Center Singapore, Singapore

  collaborator UNKNOWN

• Sun Yat-Sen University Cancer Center

  collaborator OTHER

• Tuen Mun Hospital

  collaborator OTHER_GOV

• The University of Hong Kong-Shenzhen Hospital

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-01-09

Primary Completion

2031-12-31

Completion

2031-12-31

Countries

• China

Study Locations